EPR Properties vs 10X Genomics Inc — how do they compare? EPR Properties trades at $54.41 (market cap $4.17B), while 10X Genomics Inc trades at $78.99 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 2.4× EPR Properties's market cap, and EPR Properties pays a 6.84% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 45 Days and 10X Genomics Inc for 92 Days on average.
| EPR | TXG | |
|---|---|---|
Market Cap | $4.17B | $10.07B |
Volume | 992,716 | 5,657,286 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $97.74 |
52-Week Low | $48.71 | $11.48 |
Typical Hold Time | 45 Days | 92 Days |
Enterprise Value | $7.68B | $9.59B |
Dividend Yield | 6.84% | — |
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $54.08, down 2.15% today, with a bearish technical signal and oversold RSI suggesting potential reversal. The REIT maintains strong fundamentals with 91.41% gross margins and consistent dividend payments, though recent earnings showed a Q1 miss. Analyst consensus remains positive with a $65.50 price target, representing 21% upside from current levels.
EPR offers attractive income potential with a 6.5% dividend yield and diversified real estate portfolio, but faces headwinds from rising interest rates and mixed earnings performance. The stock's current valuation at 17.44 P/E appears reasonable, though technical weakness and negative cash flow projections for 2026 warrant caution for near-term investors.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →